Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343043 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01343043 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants.
The verdict
NCT01343043, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this early (pilot) clinical trial is to test the effects (both good and bad) of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable, metastatic or recurrent synovial sarcoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG NY-ESO-1(c259)T Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-09-27 |
| Est. Completion | 2019-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01343043
The ClinicalTrials.gov registry entry for NCT01343043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01343043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01343043 about?
NCT01343043 is a clinical study titled "A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma". The purpose of this early (pilot) clinical trial is to test the effects (both good and bad) of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1 peptide in patients with unresectable, metastatic or recurrent synovial sarcoma.
What is the current status of trial NCT01343043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2012-09-27. Estimated completion is 2019-06-18.
What interventions are being tested in trial NCT01343043?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), NY-ESO-1(c259)T Cells (DRUG).
Who is sponsoring clinical trial NCT01343043?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.